Thus, the single or combinatorial use of PI3K inhibitors, such as the BKM120 used in our study, which is currently in clinical trials for several types of cancer including breast cancer, would potentially be a more appropriate and effective chemotherapy for treating obscurin-deficient breast tumors. The gene discussed is OBSCN; the disease is breast carcinoma.